EU/3/14/1352

About

On 15 October 2014, orphan designation (EU/3/14/1352) was granted by the European Commission to GlaxoSmithKline Trading Services Limited, Ireland, for raxibacumab for the treatment of inhalation anthrax disease.

The sponsorship was transferred to Emergent Countermeasures International Ltd., United Kingdom, in January 2018.

The sponsorship was transferred to Emergent Netherlands B.V., The Netherlands, in April 2019.

Key facts

Active substance
Raxibacumab
Disease / condition
Treatment of inhalation anthrax disease
Date of first decision
15/10/2014
Outcome
Positive
EU designation number
EU/3/14/1352

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Emergent Netherlands B.V.
Strawinskylaan 411
1077 XX Amsterdam
Netherlands
Tel: +31 20 301 2200
E-mail: Raxibacumab@ebsi.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating